A Three Week Dose Escalation, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of 100 mg or 200 mg of Inhaled Alpha-1 HC, Once a Day in Subjects With Cystic Fibrosis

Trial Profile

A Three Week Dose Escalation, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of 100 mg or 200 mg of Inhaled Alpha-1 HC, Once a Day in Subjects With Cystic Fibrosis

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2016

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors Grifols
  • Most Recent Events

    • 11 Jan 2016 Protocol amendment has been done in primary endpoints. Trial focus has been changed from TU & AR to AR as reported by ClinicalTrials.gov record.
    • 15 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top